Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells. A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients. DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls. Polymerase chain reaction was carried out and single nucleotide polymorphisms of FGFR4 were identified by restriction enzyme digestion. No overall association is detectable between the Arg allele and increased prostate cancer risk. Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (Po0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls. The single nucleotide polymorphism Gly 388 Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men. This observation is in contrast with results from two previous studies conducted in the USA and Japan.
Introduction
Prostate cancer (PC) is one of the most common malignancies in men in the Western world. In Scotland, age-standardized incidence rates of PC have nearly doubled over the past 25 years and PC is now the second most commonly diagnosed cancer in men (19.0% of all cancers). 1 To date, no specific factor has been identified that can account for the high incidence of PC in Scotland. Recently, fibroblast growth factor receptor 4 (FGFR4) was found to be more abundantly expressed in malignant than benign prostate cells and in vitro suppression of FGFR4 expression effectively blocked PC cell proliferation and invasion.
2 FGFR4 belongs to the family of fibroblast growth factor receptors (FGFR1-4), which are known to have key roles in biological processes such as embryo development, wound healing, cell division, angiogenesis, and regulation of cell proliferation and maturation. 3 The specific functions of FGFR4 in prostate physiology are unclear. It is a tyrosine kinase receptor consisting of an extracellular ligand-binding domain, a single transmembrane domain and a cytoplasmic regulatory domain. 4 A germ-line single nucleotide polymorphism (G-A) at position 388 of the amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) within the transmembrane domain. The Arg allele was reported to be associated with increased incidence and aggressiveness of PC. 5, 6 In this study, we hypothesized that FGFR4 Gly 388 Arg polymorphism might influence the risk of PC in Scottish men.
Materials and methods

Subjects
This study was an extension of a population-based, casecontrol study on the genetic determinants of PC risk in Scotland. 7 A consecutive series of newly diagnosed cases of primary PC patients between 50 and 75 years of age were identified in collaboration with the urology departments in the cities of Edinburgh and Glasgow and from the Scottish Cancer Registry. Benign prostatic hyperplasia (BPH) patients attending the same clinics were also approached and community controls with no history of prostate diseases were selected using the Scottish Health Service routine computer procedures. Blood was drawn from 399 PC patients, 150 BPH patients and 294 healthy community controls with informed consent and approval from the local ethics committees. All volunteers were Caucasian. Age distribution was similar in the three groups: PC patients (68.4 ± 6.0 years; mean±s.d.), BPH patients (65.9±6.1 years) and controls (68.2 ± 5.5 years). Whole-blood specimens were stored at À70 1C within 72 h of venesection. Genomic DNA was extracted from 200 ml of whole blood using a Qiagen DNA extraction kit (Qiagen, Crawley, UK) and stored at À70 1C until analysis.
Determination of single nucleotide polymorphisms
Genotyping of the FGFR4 Gly 388 Arg polymorphism was carried out as previously described. 8 Briefly, the primers 5 0 -GACCGCAGCAGCGCCCGAGGCCAG-3 0 (forward) and 5 0 -AGAGGGAAGAGGGAGAGCTTCTG-3 0 (reverse) were used in a 50 ml reaction containing 1 mg genomic DNA, 300 pmol of each primer and 2.5 U Taq polymerase (Qiagen). PCR cycling consisted of denaturation at 95 1C (5 min), 35 cycles of 95 1C for 30 s, 55 1C for 30 s and 72 1C for 1 min, followed by a final extension step at 72 1C for 7 min. The G-A transition in codon 388 creates a new BstNI restriction site. BstNI digestion of PCR product containing the Arg 388 variant resulted in two extra bands of 29 and 80 bp, whereas a single band of 109 bp was unique to the Gly 388 allele and two additional fragments (22 and 37 bp) were observed in both alleles. Restriction fragments were resolved on an 8% nondenaturing polyacrylamide gel and visualized by ethidium bromide staining.
Statistical analysis
Genotype frequencies were compared using contingency tables and w 2 -test (Minitab Release 14 Statistical Software, Minitab, State College, PA, USA). Odds ratios (OR) and their corresponding 95% confidence intervals (CI) were determined as previously described. 9 P-values o0.05 were considered statistically significant.
Results
Frequencies of the FGFR4 Gly 388 Arg genotypes in cancer, BPH and control groups are shown in Table 1 . Overall frequencies of GlyGly, ArgGly and ArgArg genotypes in the control group are 51.5, 40.2 and 8.2%, respectively. These frequencies are comparable to those reported in American Caucasians (55, 41 and 4%, respectively; n ¼ 97) 5 and a mixed group of Germans and Russians (45, 49 and 6%, respectively; n ¼ 123), 8 but are different from those observed in African Americans (81, 19 and 0%, respectively; n ¼ 94) 5 and Japanese (37, 49 and 14%, respectively; n ¼ 179), 6 (Po0.05). In our study population, no statistically significant difference in the distribution of genotypes was detectable among the three groups or between cancer cases and the combined group of controls and BPH patients (Table 1) .
Given the previously reported association between the ArgArg genotype and increased PC risk, subgroup analysis of OR was performed against the genotype with the highest frequency, GlyGly ( Table 2 ). As no difference in the distribution of genotypes was detectable between BPH patients and controls, these two groups were combined for further comparison with cancer cases. Although frequency of the ArgGly genotype in the cancer group is higher than that in the combined group of BPH and controls (OR ¼ 1.40; Po0.05), ArgGly frequencies are not different between the community control group and cancer cases (OR ¼ 1.28; P40.05).
Discussion
In view of the reported association between the FGFR4 Arg 388 allele and poor prognosis of breast, colon and squamous cell cancers in previous studies, 8, 10 we hypothesized a possible role for FGFR4 Gly 388 Arg polymorphism as a determinant of PC risk in Scottish men. The lack of association between the ArgArg genotype and increased PC risk in our study is in sharp contrast with results from a previous study conducted in the United States. 5 In the latter report, frequency of the ArgArg genotype in 284 Caucasian PC patients (15%) was higher than that in 97 Caucasian controls (4%) (Po0.01). 5 In a recent study including 492 PC patients, 165 BPH patients and 179 controls in Japan, frequencies of the ArgArg genotype were also higher in the cancer (27.0%) and BPH (25.5%) groups than in controls (14.0%, Po0.05). 6 Whether the FGFR4 Arg 388 allele is associated with either malignant neoplasm or benign hyperplasia of FGFR4 is a potential candidate gene that may determine PC risk within a population or account for differential PC incidence rates among different ethnic groups because of the receptor's possible role in regulating cell growth and differentiation in the prostate. Despite having the highest ArgArg and ArgGly genotype frequencies in the ethnic groups mentioned above, Japanese men are known to have relatively low incidence rates of PC, 11 suggesting that other genetic or environmental factors are more important determinants of PC incidence rates. Moreover, allele frequencies of FGFR4 Arg 388 among PC patients in Japanese (0.47), 6 Caucasians (0.35 in the USA 5 and 0.31 in Scotland) and African Americans in the USA (0.11) 5 are inversely related to the age-adjusted incidence and mortality rates of PC in these three ethnic groups. 11 Taken together, these observations do not support a major role for FGFR4 Arg 388 allele in the pathogenesis of PC.
